News Author: Jennifer Smith Publish date: January 28, 2019
The approval is supported by the phase 3 iLLUMINATE trial.
News Author: Jennifer Smith Publish date: January 25, 2019
The approval was based on data from the phase 2 BLAST trial.
News Author: Jennifer Smith Publish date: January 25, 2019
Umbralisib is a PI3K-delta inhibitor being developed for the treatment of adults with marginal zone lymphoma.
News Author: Jennifer Smith Publish date: January 24, 2019
LA JOLLA, CALIF. – In a small study, patients experienced relief from pruritus after just one cycle of treatment with brentuximab vedotin plus lena...
News Author: Jennifer Smith Publish date: January 24, 2019
LA JOLLA, CALIF. – Complete response rates and survival times were better among patients who received single-agent therapy.
Video Author: Jennifer Smith Publish date: January 19, 2019
LA JOLLA, CALIF. – The phase 1 study tested the addition of a histone deacetylase inhibitor to platinum-based chemotherapy.
News Author: Jennifer Smith Publish date: January 18, 2019
The drug is approved for treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction ade...
News Author: Jennifer Smith Publish date: January 18, 2019
LA JOLLA, CALIF. – Investigators said that prolonged treatment with the drug does not appear to pose an increased safety risk.
News Author: Jennifer Smith Publish date: January 18, 2019
The Bruton’s tyrosine kinase inhibitor was evaluated in a phase 2 trial.
News Author: Jennifer Smith Publish date: January 16, 2019
LA JOLLA, CALIF. – Chidamide produced a higher response rate in relapsed/refractory PTCL patients than what was observed in a prior phase 2 trial.<...
Video Author: Jennifer Smith Publish date: January 15, 2019
LA JOLLA, CALIF. – New developments include using epigenetic therapy to enhance immune checkpoint therapy and using epigenetic-based combination th...
News Author: Jennifer Smith Publish date: January 15, 2019
LA JOLLA, CALIF. – Registry data have influenced the treatment of patients with PTCL in the Czech Republic.
News Author: Jennifer Smith Publish date: January 7, 2019
The asparagine-specific enzyme is approved as part of a multiagent chemotherapy regimen.
News Author: Jennifer Smith Publish date: January 3, 2019
The FDA approved dasatinib in combination with chemotherapy for children with newly diagnosed disease.
News Author: Jennifer Smith Publish date: December 21, 2018
SAN DIEGO – The early results suggest a high overall response to the drug combination.
